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Background: New consumer health devices are being developed to easily monitor multiple physiological parameters on a
regular basis. Many of these vital sign measurement devices have yet to be formally studied in a clinical setting but have already
spread widely throughout the consumer market.
Objective: The aim of this study was to investigate the accuracy and precision of heart rate (HR), systolic blood pressure (SBP),
diastolic blood pressure (DBP), and oxygen saturation (SpO2) measurements of 2 novel all-in-one monitoring devices, the
BodiMetrics Performance Monitor and the Everlast smartwatch.
Methods: We enrolled 127 patients (>18 years) from the Thomas Jefferson University Hospital Preadmission Testing Center.
SBP and HR were measured by both investigational devices. In addition, the Everlast watch was utilized to measure DBP, and
the BodiMetrics Performance Monitor was utilized to measure SpO2. After 5 min of quiet sitting, four hospital-grade standard
and three investigational vital sign measurements were taken, with 60 seconds in between each measurement. The reference vital
sign measurements were calculated by determining the average of the two standard measurements that bounded each investigational
measurement. Using this method, we determined three comparison pairs for each investigational device in each subject. After
excluding data from 42 individuals because of excessive variation in sequential standard measurements per prespecified dropping
rules, data from 85 subjects were used for final analysis.
Results: Of 85 participants, 36 (42%) were women, and the mean age was 53 (SD 21) years. The accuracy guidelines were only
met for the HR measurements in both devices. SBP measurements deviated 16.9 (SD 13.5) mm Hg and 5.3 (SD 4.7) mm Hg
from the reference values for the Everlast and BodiMetrics devices, respectively. The mean absolute difference in DBP
measurements for the Everlast smartwatch was 8.3 (SD 6.1) mm Hg. The mean absolute difference between BodiMetrics and
reference SpO2 measurements was 3.02%.
Conclusions: Both devices we investigated met accuracy guidelines for HR measurements, but they failed to meet the predefined
accuracy guidelines for other vital sign measurements. Continued sale of consumer physiological monitors without prior validation
and approval procedures is a public health concern.
(JMIR Mhealth Uhealth 2020;8(2):e16811)  doi: 10.2196/16811
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Introduction
Background
In recent years, advances in technology and the availability of
ample venture capital have been combining to produce a
growing array of new medical diagnostic devices. New
consumer devices are being developed to easily monitor multiple
physiological parameters at home or on the go—often
connecting with mobile devices to provide user-friendly updates
of health status (mobile health). The vision behind these devices
is that they will transform conventional medicine into digital
medicine, facilitating a transition from treating disease to
promoting health, from being reactive to being proactive, from
being general to being individualized, from offering office-based
health care to bringing health care to patients, and from
interrupting daily life to being incorporated into it [1].
This vision is appealing, but presently, some of the publicized
work in the field of consumer physiological monitoring appears
to be characterized by excessive hype [2]. Many of these new
technologies have yet to be formally studied in a clinical setting,
and there are more than a few examples of digital snake oil [2]
with substantial societal uptake of devices before their eventual
discrediting [3]. This practice appears to be a barrier to truly
advancing the field of consumer physiological monitoring.
Smartwatches are one type of consumer device to easily monitor
physiological parameters on a regular basis, and more recently,
medical tricorders have been introduced. A medical tricorder
[4] is an all-in-one handheld portable device to be used by
consumers to quickly obtain several vital sign measurements
to monitor medical conditions.
Objectives
The aim of this study was to assess the accuracy of vital signs
measurements by 2 novel all-in-one physiological monitoring
devices, a smartwatch, and a medical tricorder.
Methods
Ethical Approval
This study was approved by the Institutional Review Board of
Thomas Jefferson University (IRB-nr: 18D.358), and subjects
were enrolled between June 27, 2018 and November 9, 2018.
Before participation, all subjects provided written informed
consent after all procedures and study risks were fully explained.
BodiMetrics Performance Monitor
The BodiMetrics Performance Monitor (BodiMetrics, Manhattan
Beach) is a commercially available tricorder that is sold by
several major US-based retailers such as Walmart, Amazon,
and Costco. Due to its pocket-size (88×56×13 mm), it can easily
be carried around for frequent measurement of vital signs. To
create a user profile, it requires the input of sex, date of birth,
height and weight, and an initial calibration for systolic blood
pressure (SBP) obtained with a conventional upper-arm
sphygmomanometer. The tricorder provides measurements of
SBP, oxygen saturation (SpO2), and heart rate (HR) via different
sensors, and the measurements are displayed on a touch screen.
The device uses audio and visual instructions to guide users
through a measurement; the right index finger needs to be placed
beneath the cap on top, the right thumb on the electrode on the
front, and the right middle finger on the electrode on the back
of the device (Figure 1). Then, the electrode on the left lateral
side needs to be placed in the left palm. To ensure a successful
measurement, contact needs to be maintained with all electrodes,
while the index finger is inserted under the cap. A measurement
takes about 30 seconds to complete. HR is measured through
contact with the electrodes, whereas SpO2 is measured using a
plethysmography sensor under the top flap. SBP is measured
through the determination of pulse transit time from the
electrocardiogram (ECG) and photoplethysmography signals
[5]. According to the manufacturer specifications, HR can be
measured between 30 to 210 bpm and SpO2 can be measured
between 70% and 100% [6]. The manufacturer does not provide
information about the SBP measurement range.
Figure 1. BodiMetrics Performance Monitor tricorder. Vital sign measurements are performed by placing the right index finger on the plethysmography
sensor in the right upper corner under the flap. In addition, contact has to be made with the electrocardiogram electrodes at the front, left lateral side,
and back using both hands.
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The Everlast TR10 smartwatch (Figure 2; Everlast) is a
smartwatch that is for sale through several US-based retailers
such as Walmart and Amazon. Unlike the BodiMetrics tricorder,
the Everlast smartwatch does not require any user specific
information or a calibration before use. It provides
measurements of SBP, diastolic blood pressure (DBP), and HR.
Results are shown on a display, and a button on the side is used
to navigate through the different measurements. We were unable
to verify the underlying measurement methods with the
manufacturer. The back plate of the watch contains contact
electrodes and a photoplethysmography sensor, which we
presume are utilized for the different physiological
measurements.
Figure 2. Everlast smartwatch. To enable a physiological measurement, the watch must be worn on the bare wrist making contact with the skin.
Measurements are initiated by pressing the button on the right side of the watch.
Standard Device
We used the validated Cardiocap/5 (Datex-Ohmeda)
hospital-grade vital signs monitor for reference measurements
[7]. The Cardiocap/5 has a mean blood pressure (BP)
measurement range of 25 to 260 mm Hg in adults. It uses a
plethysmography sensor to measure SpO2. HR can be measured
using ECG or can be derived from the SpO2 measurement. The
measurement range for peripheral SpO2 is 40% to 100% and
30 to 250 bpm for HR. The measurement accuracy for SpO2
between 80% and 100% is ±2% and between 50% and 80% is
±3%. The accuracy for HR is ±5% or ±5 bpm depending on
which of the two is greater [8]. The manufacturer does not
provide any information about the BP accuracy, but the device
does fulfill the American National Standards Institute
(ANSI)/Association for the Advancement of Medical
Instrumentation (AAMI)/International Organization for
Standardization (ISO) guidelines. This means that its
measurements are accurate within 5 mm Hg with a SD of ≤8
mm Hg [9,10]. To confirm the Cardiocap’s accuracy in BP
measurements, we compared Cardiocap noninvasive BP
measurements with intra-arterial BP measurements from a
previously published dataset [11]. The average absolute
difference between the two methods from six paired BP
measurements in 100 subjects (582 total pairs) was 4.3 (SD 6.8)
mm Hg for SBP and 4.8 (SD 7.2) mm Hg for DBP
measurements. This difference is within the recommended limits
for accuracy when comparing the obtained measurements from
a noninvasive monitor with intra-arterial measurements [9,10].
For BP measurements, the participant’s arm circumference was
measured, and the appropriate cuff size was chosen accordingly.
The standard adult-size cuff (REF572428) and the large
adult-size cuff (REF 572429, both Datex-Ohmeda, Inc) were
used for arm circumferences of 25 to 35 cm and 33 to 47 cm,
respectively.
Subjects
We recruited study participants, aged more than 18 years, from
patients visiting the Thomas Jefferson University Hospital
Preadmission Testing Center. Exclusion criteria were as follows:
(1) contraindication for automated BP measurement on both
arms for reasons including but not limited to a history of breast
cancer surgery with radiation therapy or axillary lymph node
dissection, arteriovenous fistula for hemodialysis, or an open
wound; (2) irregular heart rhythms such as atrial fibrillation and
atrial flutter; (3) missing upper extremity, hand, or finger; (4)
inability to wear a watch because of wrist circumference or
edema of the arm, wrist, or hand; (5) lack of appropriate-sized
BP cuff; and (6) pacemaker or other implanted medical device
[6].
Testing Procedure
Research staff were trained to measure BP, SpO2, and HR with
the Everlast smartwatch, BodiMetrics tricorder, and Cardiocap/5
according to their manufacturers’ guidelines. The investigational
devices used in the study were new devices and were acquired
through Amazon shortly before the study commenced. We
followed a validation protocol derived from the
ANSI/AAMI/ISO 2013 standards for evaluating noninvasive
automated sphygmomanometers [3,9,10]. Study procedures
were explained, and participants were seated in a chair with
back support and armrests, with both feet on the floor; subjects
were instructed not to cross their legs or speak during the study.
After 5 min of rest, the measurement protocol began with an
initial standard measurement and a calibration measurement for
the BodiMetrics tricorder (Figure 3). After this calibration,
sequential measurements were taken, alternating between the
reference and the investigational devices, with 60 seconds in
between each measurement. This yielded a pattern where two
standard measurements bounded each investigational device
measurement [9,10]. In total, four standard and three
investigational device measurements were obtained per
participant. If a measurement with one of the investigational
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devices failed, up to two additional attempts were made.
Participants were blinded to the standard measurements but not
to the investigational measurements as these required the
participants’ interaction with the devices.
Data and Statistical Analysis
The reference SBP, DBP, HR, and SpO2 values were all
calculated by determining the average of the two standard vital
sign measurements that bounded the investigational
measurements (Figure 3). This yielded three
reference-investigational comparison pairs for the different vital
signs for each device. As our protocol was derived from a BP
validation protocol, we excluded data from subjects with a
variation in standard measurements greater than 12 mm Hg for
SBP and 8 mm Hg for DBP, in accordance with validation
guidelines [9,10].
For BP measurement validation, the main outcome was the
mean (SD) of the absolute difference between the respective
investigational devices and the reference values for SBP and
DBP [9,10]. The BP measurement results have been presented
elsewhere previously [12] and are reported again with
permission. BP measurements by the investigational devices
were considered accurate if the mean absolute difference was
≤5 mm Hg with a SD of ≤8 mm Hg [9,10]. Accuracy of the BP
measurements by the investigational devices was also graded
according to the classification from the British Society of
Hypertension [13,14].
For HR measurement validation, the main outcomes were the
mean of the absolute difference between the respective
investigational devices and the reference values, and the percent
absolute difference between the respective investigational
devices and the reference values. HR measurements were
considered accurate if the mean absolute difference was within
either ±10% or ±5 bpm, depending on which of the two was
greater [15].
For SpO2, the main outcome was the root mean square error
(RMSE) between the respective investigational devices and the
reference values. SpO2 measurements were considered accurate
if the mean RMSE was ≤3.0% [16].
The main outcome data were visualized using Bland-Altman
plots (Sigmaplot, version 14, Systat Software Inc). The dotted
line in the Bland-Altman plot represents the mean relative
difference (investigational minus reference), and the dashed
lines represent ±1.96 SDs for the absolute difference. In
addition, correlation analyses and scatterplots were utilized to
assess the relation between the respective investigational devices
and the reference values. To aid in the interpretation of clinical
applicability of these devices, we also assessed the rates at which
they successfully detected values for vital signs that were
measured outside the normal range by reference values (≥140
mm Hg SBP, ≥90 mm Hg DBP, <60 bpm HR, or <90% for
SpO2). The solid line in the scatterplots represents the line of
identity. The dashed lines in the scatterplots for BP, HR, and
SpO2 represent the cutoff for stage 2 hypertension, bradycardia,
and hypoxemia, respectively. Normality of values was assessed
using the Shapiro-Wilk test. In the case of normally distributed
residuals, Pearson correlation analysis was performed, and in
the case of non-normally distributed residuals, Spearman
correlation analysis was performed. Means are reported with
SD for all variables. Nominal variables are reported as n with
relative proportion in percentage.
All data files are available from the Data Archiving and
Networked Services database [17].
Figure 3. Study timeline. B: BodiMetrics Performance Monitor measurement; E: Everlast smartwatch measurement; S: Standard measurement (light
grey color). The dark grey color indicates the investigational devices.
Results
Principal Results
We enrolled a total of 127 subjects, and data from 41
participants were discarded because of excessive variation in
sequential standard BP measurements, as specified by the
ANSI/AAMI/ISO 2013 standards for evaluating noninvasive
automated sphygmomanometers [3,9,10], and from 1 participant
because of repeated failure of BodiMetrics calibration; 85
subjects were included in the final analysis. Demographics and
characteristics of the study population are displayed in Table
1. These data have previously been presented by Van Helmond
et al [12] and are reproduced with permission.
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Table 1. Validation study: participant characteristics (n=85).
ValuesParticipant characteristics
125 (15)Systolic blood pressure at baseline (mm Hg), mean (SD)
76 (9)Diastolic blood pressure at baseline (mm Hg), mean (SD)
72 (12)Heart rate at baseline (bpm), mean (SD)
96 (2)Oxygen saturation at baseline (%), mean (SD)
53 (21)Age (years), mean (SD)









28 (33)High school or General Educational Diploma
38 (45)College or university degree
6 (7)Master’s degree
5 (6)Doctorate
Self-reported medical history, n (%)
32 (38)Hypertension
31 (36)Taking medication for hypertension
13 (15)Diabetes
12 (14)Taking medication for diabetes
3 (4)Heart attack
3 (4)Taking medication for heart attack
2 (2)Heart failure
1 (1)Taking medication for heart failure
2 (2)Peripheral vascular disease
2 (2)Taking medication for peripheral vascular disease
1 (1)Stroke




The BodiMetrics tricorder failed in 6 (7%) participants for a
total of 13 (5%) of the maximum 255 BP measurements that
could have been obtained in the 85 participants. The average
absolute difference between the BodiMetrics tricorder and the
reference was 5.3 (SD 4.7) mm Hg for SBP (Figure 4). The
performance monitor, thus, failed to meet the predefined
accuracy target for SBP measurements [9,10]. According to the
British Society of Hypertension guidelines, the BodiMetrics is
a grade-B BP monitor [13,14]. BodiMetrics tricorder
measurements correlated well with reference measurements
(ρ=0.88; P<.001); the BodiMetrics tricorder measured a
hypertensive BP value (≥140 mm Hg) for 80% of the
hypertensive reference SBP values (Figure 4).
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Figure 4. Systolic blood pressure (A and B), heart rate (C and D), and oxygen saturation (E and F) measurements by BodiMetrics tricorder and reference
values. SBP: systolic blood pressure, HR: heart rate, SpO2: oxygen saturation.
Heart Rate
The BodiMetrics tricorder failed in 3% (3/85) participants for
a total of 3.1% (8/251) HR measurements. The average absolute
difference between the BodiMetrics tricorder and the reference
values was 1.8 (SD 1.8) bpm (Figure 4). The mean absolute
percentage difference was 2.5 (SD 2.5) %. The BodiMetrics
tricorder, therefore, met the predefined accuracy cutoff for HR
measurements [15]. Correlation analysis revealed a statistically
significant, strong correlation (ρ=0.97; P<.001; Figure 4)
between the BodiMetrics tricorder HR measurements and the
reference values. The BodiMetrics tricorder measured a
bradycardic HR value (<60 bpm) for 90% of the bradycardic
reference HR measurements (Figure 4).
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The BodiMetrics tricorder failed in 4% (4/85) participants for
a total of 3.5% (9/257) SpO2 measurements. The RMSE for
SpO2 between BodiMetrics Performance Monitor measurements
and reference values was 3.1% (Figure 4). The BodiMetrics
Performance Monitor measurements, thus, failed to meet the
predefined accuracy standard [16]. BodiMetrics Performance
Monitor SpO2 measurements were moderately correlated with
reference values (ρ=0.44; P<.001; Figure 4). The BodiMetrics
tricorder measured no hypoxic SpO2 values (<90%) for any of
the hypoxic reference SpO2 measurements (Figure 4).
Everlast TR10 Smartwatch
Blood Pressure
The Everlast watch failed in 38% (33/85) participants for a total
of 34.1% (87/255) BP measurements. The average absolute
differences between the Everlast watch and reference were 16.9
(SD 13.5) mm Hg for SBP and 8.3 (SD 6.1) mm Hg for DBP
(Figure 5). The watch’s performance, thus, failed to meet the
predefined accuracy guideline for SBP and DBP measurements
and is considered a grade-D monitor for SBP and DBP
measurements according to the British Society of Hypertension
guidelines [9,13,14]. The difference between the Everlast watch
and reference measurement was dependent on the SBP value,
such that lower SBPs were estimated higher and higher SBPs
were estimated lower (ρ=−0.45; P<.001; Figure 5). Everlast BP
measurements were not correlated with reference BP
measurements, and the Everlast watch failed to measure any
hypertensive BP values for any of the hypertensive reference
SBP or DBP measurements (Figure 5).
Heart Rate
The Everlast watch failed in 36% (31/85) participants for a total
of 31.8% (81/255) HR measurements. The average absolute
difference between the Everlast watch and the reference was
6.5 (SD 9.2) bpm (Figure 5). The mean absolute percentage
difference was 9.9 (SD 14.3) %. The Everlast watch, therefore,
met the predefined accuracy guidelines [15]. Correlation analysis
revealed a significant moderate correlation (ρ=0.7; P<.001)
between the Everlast watch HR measurements and the reference
values (Figure 5). The Everlast smartwatch measured a
bradycardic HR value (<60 bpm) for 33% of the bradycardic
reference HR measurements (Figure 5).
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Figure 5. Systolic blood pressure (A and B), diastolic blood pressure (C and D), and heart rate (E and F) measurements by Everlast smartwatch and
reference values. BP: systolic blood pressure, DBP: diastolic blood pressure, HR: heart rate.
Discussion
Principal Findings
The aim of this study was to assess the accuracy of vital sign
measurements by 2 novel, all-in-one physiological monitoring
devices, a smartwatch, and a medical tricorder. We found that
the accuracy guidelines for HR measurements were met by both
investigational devices. However, neither device met the
accuracy guidelines for BP measurements. The SpO2
measurements by the BodiMetrics also did not meet the accuracy
guidelines for transmissive pulse oximetry. The absolute or
relative differences from the reference measurements were very
large for the Everlast watch, whereas the BodiMetrics’
measurements were closer to meeting the predefined standards.
The results of our study indicate that the Everlast smartwatch
is not accurate enough to be used to monitor vital signs. For the
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BP measurements, the Everlast smartwatch did not correctly
measure any (0%) of the hypertensive values for the values that
were hypertensive when measured with the standard cuff.
Although the watch met our predefined accuracy standard for
HR, it detected only 33% of the bradycardic HR values that
were measured by the standard monitor. In addition to the
accuracy problems, the watch failed to obtain any measurement
at all for 32% of HR and 34% of SBP and DBP measurements.
We are not aware of any prior studies on the Everlast smartwatch
to compare the findings of this study with, but we found 3
studies by a Dutch research group on the BodiMetrics
Performance Monitor, which is marketed in Europe under the
name Checkme [5,18,19]. A study by Schoot et al [5] compared
the SBP measurements obtained with the BodiMetrics
Performance Monitor with the SBP measurements obtained by
a reference automated cuff in 37 outpatients in supine position
and sitting position and found average absolute differences of
approximately 6.7 (SD 5.4) mm Hg in supine position and
approximately 10.1 (SD 7.0) mm Hg in sitting position. The
average absolute difference they found is somewhat larger than
the difference we found in this study (5.3 [SD 4.7] mm Hg).
An underlying reason for this difference may be that the bias
calculation in their study did not average the two standard
measurements that bounded each investigational measurement,
and that naturally occurring drift in BP, thus, may have
exaggerated the detected difference [9]. They also did not
exclude any subjects based on drift in standard measurements,
as we did per the ANSI/AAMI/ISO BP monitor validation
protocol [9]. In a subsequent study by Weenk et al [18], the
same group compared all vital signs measured by the
BodiMetrics with a standard hospital-grade monitor in 41
Internal Medicine inpatients. They found an average absolute
difference of 10.7 (SD 11.0) mm Hg between BodiMetrics SBP
measurements and the reference. For HR, the average absolute
difference was 2.9 (SD 2.9) bpm, and for SpO2, the RMSE was
4.2% [18]. These BodiMetrics-to-reference differences are
substantially greater than the difference we encountered and
are potentially because of a smaller dataset of 69 data pairs per
vital sign compared with our 242 BP, 246 SpO2, and 247 HR
data pairs. There were also differences in the measurement
protocol between the Weenk et al’s study [18] and this study.
They obtained data from inpatients in supine position, whereas
our subjects were seated outpatients. Moreover, we averaged
bounding standard measurements to reduce the influence of
drift, whereas Weenk et al [18] did not. Another difference is
that they performed calibration of the BodiMetrics once in the
morning and then collected data on three different time points
during the day, whereas our measurements were taken in the
approximately 20 to 30 min following calibration [18]. The
subject’s BP may have changed significantly from the value at
which the BodiMetrics was calibrated in their study, which
might have affected the accuracy of the measurements. In
contrast, the BP during our protocol was likely similar to the
calibration value [20]. In a third study from the same group,
Ogink et al [19] compared BodiMetrics SBP measurements
with SBP measurements obtained at home by 11 patients with
hypertension using various home automated BP monitors over
3 weeks. BodiMetrics SBP measurements were found to be
weakly correlated to cuff SBP measurements, and there was a
large absolute difference between the two measurements (eg,
44% of measurements differed by >10 mm Hg). Although the
accuracy of the BodiMetrics is difficult to assess from this study,
considering there was no standardized monitor or measurement
protocol, the reported low accuracy appears to indicate that the
BodiMetrics SBP measurement becomes significantly more
inaccurate when some time passes since calibration.
To address concerns related to BP calibration dependency, an
alternative validation protocol specific to cuff-less monitors has
been suggested by the Institute of Electrical and Electronics
Engineers (IEEE). This validation protocol requires the same
accuracy as the ANSI/AAMI/ISO standard for cuff-based
devices, but it differs from the ANSI/AAMI/ISO protocol, in
that it includes validation measurements after artificial changes
in BP are induced after initial calibration to ensure accuracy
over a wide range of BP values. In addition, the IEEE protocol
includes validation measurements obtained after a significant
period (weeks to months) since the initial calibration to
investigate time-dependent calibration integrity [20]. We did
not induce different BPs or investigate time-dependent changes
in accuracy in this study.
To assess whether the BodiMetrics accuracy may be affected
by changes in BP from the calibration value, we performed a
posthoc analysis on the difference between the reference values
and the BodiMetrics SBP measurements versus the difference
in the reference values and the calibration value (Figure 6). We
found a significant moderate correlation between these two
absolute differences, indicating that the accuracy of the
BodiMetrics tricorder incrementally decreases when it is used
at incrementally different pressures from the calibration value.
These findings would need to be confirmed in a prospective
manner while consciously changing BP in study subjects to
warrant any definitive conclusions. On the basis of our findings,
we conclude that the current calibration process demonstrates
a limitation of the BodiMetrics tricorder that should be further
examined.
With regard to the initial calibration of the BodiMetrics, Weenk
et al [18] reported that in 18% of the participants the calibration
procedure failed and that the main reasons for failed calibration
were shivering and cold hands. In the study conducted by Schoot
et al [5], 12 of the 52 (23%) volunteers were excluded because
of repeated calibration failure. We started our study during the
hot summer months and only recognized a correlation between
calibration issues and cold hands in 1 participant who was tested
in late October. Overall, our calibration failure rate was lower
than that reported by Weenk et al [18] who conducted their
study between March and May [18]. As reported in the
BodiMetrics’ users guide, dry and cold hands can influence the
connectivity between hands and electrodes [5]. The conductivity
is also affected by a thick stratum corneum [21]. The study by
Weenk et al [18] found no correlation between patient gender,
age, or weight and failure of calibration. As we only observed
a failure in calibration at first or second attempt in 4.7% of
attempts, we were not able to study any of these relationships.
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Figure 6. Difference between BodiMetrics tricorder systolic blood pressure measurements and calibration measurement versus difference between
reference systolic blood pressure measurements and calibration measurement. The solid line in the scatterplot represents the line of identity. Data shown
were not normally distributed (Shapiro-Wilk test).
Practical Implications and Future Directions
Use of devices such as the Everlast smartwatch may result in
individuals incorrectly assuming that they are, for example,
normotensive or hypertensive. This might delay diagnosis or
result in incorrect medication self-adjustments. The BodiMetrics
tricorder’s accuracy for SBP and HR was considerably better
than the accuracy of the Everlast smartwatch in this study.
However, the BodiMetrics tricorder did not meet the predefined
accuracy standards for SBP and SpO2 measurements. The
BodiMetrics tricorder has approval for measurements of SpO2
and HR from the US Food and Drug Administration, but not
for measurement of SBP [22]. The results of this study suggest
that it is doubtful that the tricorder should be used for SBP or
SpO2 measurements. Proper validation of consumer vital sign
monitors before commercial release would aid in avoiding the
potential serious repercussions of inaccurate vital sign
measurements.
Limitations
A limitation that pertains to this study is that we modified the
BP monitor validation protocol that our study was based on by
using an automated hospital vital signs monitor instead of a
mercury sphygmomanometer [14] and auscultation. We made
this adjustment to accommodate the assessment of different
vital signs in one protocol and this adjustment is based on the
precedent that other groups have set by following a similar
approach [3,5,18,19]. In the near feature, we aim to conduct a
study on cuff-less BP monitors using a mercury
sphygmomanometer as a reference.
Another area of interest for future studies is the accuracy and
precision of consumer vital sign monitors in real-world settings
by individuals in their home environment, as that is where these
devices are ultimately being used [19]. Such studies could also
address whether issues related to maintenance, servicing, and
wear and tear of devices adversely affect performance.
Conclusions
The Everlast TR10 smartwatch is not accurate enough to be
used as a vital sign’s measurement device. The BodiMetrics
device was substantially more accurate, but it still failed to meet
predefined accuracy guidelines for SBP and SpO2. The
continued sale of consumer physiological monitor devices
without the required prior validation and market approval
procedures is a significant public health concern.
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